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Platinum nanoparticles are being utilized in various industrial applications, including in catalysis, cosmetics, and
dietary supplements. Although reducing the size of the nanoparticles improves the physicochemical properties and
provides useful performance characteristics, the safety of the material remains a major concern. The aim of the
present study was to evaluate the biological effects of platinum particles less than 1 nm in size (snPt1). In mice
administered with a single intravenous dose of snPt1, histological analysis revealed necrosis of tubular epithelial
cells and urinary casts in the kidney, without obvious toxic effects in the lung, spleen, and heart. These mice
exhibited dose-dependent elevation of blood urea nitrogen, an indicator of kidney damage. Direct application of
snPt1 to in vitro cultures of renal cells induced significant cytotoxicity. In mice administered for 4 weeks with twice-
weekly intraperitoneal snPt1, histological analysis of the kidney revealed urinary casts, tubular atrophy, and
inflammatory cell accumulation. Notably, these toxic effects were not observed in mice injected with 8-nm
platinum particles, either by single- or multiple-dose administration. Our findings suggest that exposure to platinum
particles of less than 1 nm in size may induce nephrotoxicity and disrupt some kidney functions. However, this
toxicity may be reduced by increasing the nanoparticle size.
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Nanomaterials have been developed and used as innova-
tive materials in a wide range of industrial fields, includ-
ing electronics, medicine, food, clothing, and cosmetics;
these reagents are expected to provide significant bene-
fits to humans. Nanomaterials are defined as substances
that have at least one dimension size below 100 nm. The
reduced size provides novel physicochemical properties,
including increased thermal electrical conductivity, dur-
ability, and strength [1-3]. Although these characteristics
may yield improved performance and novel functions,
several reports have suggested that various types of
nanomaterials, such as carbon nanotubes, titanium diox-
ide, fullerenes, quantum dots, and silica, exhibit harmful
biological effects [4-12]. Additionally, some reports have
shown that the characteristics of nanoparticles (e.g., size
and surface features) can affect their biological and* Correspondence: akihiro@phs.osaka-u.ac.jp
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in any medium, provided the original work is ppathological actions [10,13-16]. Therefore, evaluation of
the potential health risks attributable to nanomaterials is
indispensable for the safe handling and use of these ma-
terials. However, little information is available regarding
the safety evaluation of materials less than 1 nm in size.
Platinum nanoparticles have been utilized in a number
of manufacturing applications, including catalysis, cos-
metics manufacturing, and the processing of dietary sup-
plements. As products using platinum nanoparticles
become more familiar in our daily lives, the chances of
exposure to platinum nanoparticles are increasing, as
are concerns about unanticipated harmful biological
effects of these materials [17,18]. In fact, there are some
reports that platinum nanoparticles can induce inflam-
mation in mice or impair the integrity of DNA [19,20].
On the other hand, platinum nanoparticles have anti-
oxidant activity and inhibit pulmonary inflammation
(e.g., as caused by exposure to cigarette smoke) [21-23].
These reports indicate that the biological effects of plat-
inum nanoparticles remain poorly defined; the biological
safety of sub-nanosized platinum particles (those of lessis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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reported that snPt1 can induce hepatotoxicity [24]. How-
ever, the biological effects of snPt1 on other organs remain
unclear. In this study, we evaluated the effect of snPt1 on
tissues after single- and multi-dose administration in mice.
In addition, we investigated the relationship between plat-
inum particle size and biological response by also testing
platinum particles of 8 nm in size (snPt8).
Methods
Platinum particles
Platinum particles with nominal mean diameters of less
than 1 nm (snPt1) and 8 nm (snPt8) were purchased
from Polytech & Net GmbH (Rostock, Germany). The
particle sizes were confirmed using a Zetasizer Nano-ZS
(Malvern Instruments, Malvern, UK). The particles were
stocked as 5 mg/ml aqueous suspensions. The stock so-
lutions were suspended using a vortex mixer before use.
Other reagents used in this study were of research
grade.
Animals
BALB/c and C57BL/6 male mice were obtained from




Figure 1 Histological analysis of the organs in snPt1-treated mice. Ve
mice. At 24 h after administration, the kidney (A), lung (B), heart (C), and s
sections were stained with hematoxylin and eosin and observed microscopand were housed in an environmentally controlled room
at 23°C ± 1.5°C with a 12-h light/12-h dark cycle. Mice
had ad libitum access to water and commercial chow
(Type MF, Oriental Yeast, Tokyo, Japan). BALB/c mice
were injected intravenously with snPt1 or snPt8 at 5 to
20 mg/kg body weight. C57BL/6 mice were injected in-
traperitoneally with snPt1 or snPt8 at 10 mg/kg body
weight, or with an equivalent volume of vehicle (water).
At 24 h after the injection of the vehicle or test article,
the kidney and liver were collected. For testing the
chronic effects of platinum particles, C57BL/6 mice were
injected intraperitoneally with snPt1 or snPt8 at 10 mg/kg
body weight, or with an equivalent volume of vehicle
(water). Intraperitoneal doses were administered as twice-
weekly injections for 4 weeks. At 72 h after the last injec-
tion of vehicle or test article, the kidney and liver were
collected. All experimental protocols conformed to the
ethical guidelines of the Graduate School of Pharmaceut-
ical Sciences at Osaka University.
Histological analysis
For animals dosed intravenously with snPt1 or snPt8, the
kidney, spleen, lung, heart, and liver were removed at 24 h





hicle (water) or snPt1 (15 mg/kg) was administered intravenously to







































Figure 2 Biochemical analysis in snPt1-treated mice. (A) Dose
dependency of snPt1-induced kidney injury. snPt1 was administrated
intravenously at 5, 10, 15, or 20 mg/kg. At 24 h after administration,
blood was recovered, and serum was collected and used for
measurement of BUN, as described in the ‘Methods’ section. Data
are mean ± SEM (n = 6 to 10). Single asterisk (*) connotes a
significant difference when compared with the vehicle-treated
group (P < 0.05). (B) Time-dependent changes in a biological marker
of kidney injury. snPt1 was administered intravenously to mice at 20
mg/kg. Blood was recovered at 0, 3, 6, 12, 24, and 48 h after
administration. Serum was collected and used for measurement of
BUN, as described in the ‘Methods’ section. Data are mean ± SEM (n = 8
to 10). Single asterisk (*) connotes significant difference when compared
with the vehicle-treated group (P < 0.05).
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kidney and liver were removed at 24 h (for single adminis-
tration) or 72 h (for multiple administration) post-injection
and fixed with 4% paraformaldehyde. Thin tissue sections
were stained with hematoxylin and eosin for histological
observation.
Biochemical assay
Serum blood urea nitrogen (BUN) was measured using a
commercially available colorimetric assay kit (Wako
Pure Chemical, Osaka, Japan) according to the manufac-
turer’s protocol. In brief, collected serum (10 μl) was
combined with 1 ml color A reagent (including urease)
and incubated at 37°C for 15 min. Following the addition
of 1 ml Color B reagent, the samples were incubated at
37°C for 10 min. Absorbance of samples was measured
at a wavelength of 570 nm.
Statistical analysis
Data are presented as mean ± SEM. Statistical analysis
was performed by Student’s t test. P < 0.05 was consid-
ered significant.
Results and discussion
To investigate acute biological effects of snPt1, we ad-
ministered 15 mg/kg of snPt1 to BALB/c mice by intra-
venous injection and performed histological analysis in
the kidney, lung, heart, liver, and spleen at 24 h post-
injection. As shown in Figure 1, necrosis of tubular epithe-
lial cells and urinary casts were observed in the kidney by
hematoxylin-eosin staining, whereas no apparent tissue
abnormality was observed in the lung, heart, and spleen.
Consistent with previous results [24], the liver showed
vacuole degeneration after the administration of snPt1
(data not shown). These observations indicate that snPt1
induced acute tissue injury in the kidney and liver follow-
ing intravenous administration. Next, we examined a
serum biochemical marker of kidney function, BUN, to
confirm the kidney tissue toxicity. Consistent with the
histological analysis, intravenous dosing with snPt1
elevated serum BUN level at doses over 15 mg/kg
(Figure 2A). The serum BUN level increased 24 h later
and returned to normal level after 48 h (Figure 2B). When
we directly added snPt1 at concentrations of 10, 20, 40,
and 60 μg/ml to in vitro cultures of Madin-Darby canine
kidney (MDCK) cells, severe cytotoxicity was observed in
a dose-dependent manner (Additional file 1: Figure S1).
These results indicate that snPt1 (at doses of greater than
or equal to 15 mg/kg) induced toxicity in both the kidney
and liver, but not in the lung, heart, or spleen, after a sin-
gle intravenous administration.
Previously, we and other groups reported that the bio-
logical effects of nanoparticles differed with material size
[10,11,25,26]. Therefore, we examined whether platinumparticles with a diameter of 8 nm (snPt8) and snPt1 pro-
duce different effects in kidney. As shown in Figure 3A,
snPt1 administration resulted in dose-dependent in-
























mg/kg 0 20 20
Urinary cast 0 3 0
Necrosis of tubular epithelial cell 0 3 0
Vehicle snPt1 snPt8
Tubular atrophy 0 0 0
Inflammatory cell infiltration 0 0 0
C
Grade 0:none 1:slight, 2:mild, 3:moderate, 4:severe
Figure 3 Effect of particle size of platinum on kidney injury. (A) snPt1 or snPt8 was injected intravenously into mice at the indicated doses.
Blood was recovered at 24 h after injection. Serum BUN levels were measured. Data are mean ± SEM (n = 5). Double asterisk (**) connotes
significant difference between the snPt1- and snPt8-treated groups (P < 0.01). (B) Histological analysis of kidney tissues in acute snPt1- or snPt8-
treated mice. Vehicle or test article (snPt1 or snPt8 at 20 mg/kg) was administered intravenously to mice as a single dose. At 24 h after
administration, the kidneys were collected and fixed with 4% paraformaldehyde. Tissue sections were stained with hematoxylin and eosin and
observed under a microscope. (C) Acute kidney injury score in mice treated with vehicle, snPt1, or snPt8. Grade 0: none, 1: slight, 2: mild, 3:
moderate, 4: severe.
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intravenous administration (at 20 mg/kg) of snPt1, but
not that of snPt8, induced renal injury (Figure 3B,C).
These tissue injuries also were observed following theinjection in C57BL/6 mice (data not shown), demon-
strating that the toxicity was not mouse strain-specific.
Furthermore, renal cytotoxicity was not observed in
snPt8-treated MDCK cells (Additional file 1: Figure S1),
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cytotoxicity. The hepatotoxicity of the platinum particles
also was reduced by altering particle size [24]. These
findings indicate that the snPt1-induced nephrotoxicity
is not observed following treatment with the same dose
level of snPt8.
Finally, we used histological analysis to investigate the
effects on C57BL/6 mice of chronic exposure to snPt1
and snPt8. snPt1 and snPt8 (both at 10 mg/kg) were
injected intraperitoneally into mice twice per week for 4
weeks; repeat administration via the tail vein was pre-
cluded due to tissue necrosis of the mouse tail upon
multiple intravenous administrations. In the multiple in-
traperitoneal administrations, necrosis at the injection
site was not observed. Single intraperitoneal administra-
tion of 10 mg/kg snPt1 (but not that of snPt8) induced
necrosis of tubular epithelial cells and urinary casts in
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Figure 4 Histological analysis of kidney tissues in multi-dose snPt1- o
mg/kg) was administered intraperitoneally to mice as twice-weekly doses f
collected and fixed with 4% paraformaldehyde. Tissue sections were staine
(B) Chronic kidney injury scores in mice treated with vehicle, snPt1, or snPtadministration (Additional file 2: Figure S2A,B). Chronic
intraperitoneal administration of snPt1 at 10 mg/kg in-
duced urinary casts, tubular atrophy, and inflammatory
cell accumulation in the kidney, whereas the liver did
not show tissue injury (Figure 4A,B). On the other hand,
chronic exposure to snPt8 (at the same dose level) did
not show apparent histological effects in the kidney
(Figure 4A,B). These findings suggest that chronic ex-
posure to 10 mg/kg snPt1, but not to snPt8, induced
severe kidney injury. Notably, this chronic exposure to
snPt1 induced additional (cumulative) kidney injury
beyond that seen with acute exposure.
Following exposure, nanoparticles are transported into
the blood and reach the systemic circulation, from which
the nanoparticles distribute and accumulate in several
organs such as the lung, liver, spleen, kidneys, brain, and
heart [27-30]. Because the kidney is able to remove mole-








r snPt8-treated mice. (A) Vehicle or test article (snPt1 or snPt8 at 10
or 4 weeks. At 72 h after last administration, the kidney and liver were
d with hematoxylin and eosin and observed under a microscope.
8. Grade 0: none, 1: slight, 2: mild, 3: moderate, 4: severe.
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ized single-wall carbon nanotubes (SWCNT), following
injection into mice, are rapidly excreted by the kidney
[31]. The hepatobiliary system also is an important route
for the elimination of foreign substances and particles
[32]. Because these organs play pivotal roles in eliminating
foreign substances, various nanomaterials are accumulated
there and lead to tissue injury. As one example, our previ-
ous work showed that snPt1-treated mice exhibited acute
hepatotoxicity [24]. In the present study, we investigated
the biological effects of snPt1 after intravenous or intra-
peritoneal administration in mice and demonstrated that
snPt1 induced nephrotoxicity and impaired renal function,
as evidenced by BUN levels. In contrast, we could not find
apparent toxic effects on the heart, lung, or spleen after
the single intravenous administration of snPt1, although
the disposition of these nanoparticles will need to be
assessed further.
The underlying mechanism of snPt1-induced tissue in-
jury still remains unclear. Cisplatin, which is a platinating
agent used as part of the anti-cancer regimen for various
types of cancers [33,34], exerts its antitumor activity by
binding preferentially to the nucleophilic positions on
guanine and adenine of DNA, resulting in the formation of
intra- and inter-strand crosslinks. Eventually, the crosslinks
lead to DNA-strand breaks and killing of cancer cells [35].
However, cisplatin usage is limited due to nephrotoxicity,
leading to lesions in the epithelial tubules [36,37]. Cisplatin
also causes toxicity in the liver and blood [38]. These
observations suggest that the toxic effects of cisplatin
resemble those of snPt1. A previous study reported
that platinum nanoparticles entered human lung fibro-
blasts (cell line IMR-90) and human glioblastoma cells
(U251) and induced cytotoxicity thorough intracellular
reactive oxygen species (ROS) production and DNA
damage following p53 activation and upregulation of
p21, which leads to growth arrest and apoptosis [39].
Our observation of snPt1-induced cytotoxicity in cell
culture suggests that snPt1 may be internalized by
renal cells, with concomitant induction of ROS produc-
tion or DNA damage. However, alternative toxic effects
(such as cytotoxicity of inflammatory cytokines on renal
cells by accumulation of inflammatory cells in the kidney)
might emerge during chronic exposure to snPt1.
At equivalent dose levels, platinum particles of 8 nm in
size did not induce apparent toxic effects in renal tissues
by acute or chronic administration. This result suggests
that selection of specific size ranges for the platinum parti-
cles might overcome the undesirable side effects. Current
studies have shown that organic cation transporter 2
(OCT2) is highly expressed in kidney and plays an import-
ant role in the nephrotoxicity of cisplatin [40,41]. Identifi-
cation of the snPt1 transporter may help to clarify the
mechanism of snPt1-induced nephrotoxicity.Conclusions
In the present study, we investigated the biological safety
of platinum nanoparticles in mice and found that plat-
inum particles of less than 1 nm induced kidney injury,
although the injurious effects were reduced by increasing
the nanoparticle size. For future nanoparticle applica-
tions, it will be critical to further understand the bio-
activity and kinetics of materials less than 1 nm in size.
Accumulation of toxicity profiles will aid in the creation
of the safe and efficacious nanomaterials and contribute
to the advancement of the field.
Additional files
Additional file 1: Figure S1. Cytotoxicity of snPt1 in renal cells. MDCK
cells were treated with vehicle, snPt1, or snPt8 at 0, 10, 20, 40, or 60 μg/
ml. After 24 h exposure, morphology of the cells was photographed.
Higher magnification images are shown in the insets.
Additional file 2: Figure S2. (A) Histological analysis of kidney tissues
in intraperitoneally administered mice. Vehicle or test article (snPt1 or
snPt8 at 10 mg/kg) was administered intraperitoneally to mice as a single
dose. At 24 h after administration, kidneys were collected and fixed with
4% paraformaldehyde. Tissue sections were stained with hematoxylin and
eosin and observed under a microscope. (B) Acute kidney injury score in
mice treated intraperitoneally with vehicle, snPt1, or snPt8. Grade 0: none,
1: slight, 2: mild, 3: moderate, 4: severe.
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